Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2FED 2

Study Type

Interventional 2

Sponsor

Conditions

Rare Diseases 2Dupuytren Contracture 2Connective Tissue Diseases 2Arthritis 2

Interventions

Exercise 6pembrolizumab 5enzalutamide 4Docetaxel 4Colonoscopy 4Celecoxib 4sargramostim 3apalutamide 3Prednisone 3Methods 3Leuprolide 3Itraconazole 3Imiquimod 3Granulocyte-Macrophage Colony-Stimulating Factor 3Golytely 3Cryotherapy 3Abiraterone Acetate 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3abiraterone 2Yoga 2Topotecan 2Testosterone 2Tablets 2Simvastatin 2Radiosurgery 2Palliative Care 2Midazolam 2Gelatin 2Decision Support Techniques 2Collagenases 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
FED × Interventional × Collagenases × Clear all
NCT00004409 2015-03-25

Phase II Randomized Study of Collagenase in Patients With Residual Type Dupuytren's Disease

FDA Office of Orphan Products Development

Phase 2 Completed
36 enrolled

Arthritis, Connective Tissue Diseases, Dupuytren Contracture, Rare Diseases

NCT00014742 2015-03-25

Phase III Randomized Study of Collagenase in Patients With Residual Stage Dupuytren's Disease

FDA Office of Orphan Products Development

Phase 3 Completed
72 enrolled

Arthritis, Connective Tissue Diseases, Dupuytren Contracture, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡